Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2017 - 2025)

Neurocrine Biosciences' Other Accumulated Expenses history spans 14 years, with the latest figure at $69.1 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses rose 49.89% year-over-year to $69.1 million; the TTM value through Dec 2025 reached $69.1 million, up 49.89%, while the annual FY2025 figure was $69.1 million, 49.89% up from the prior year.
  • Other Accumulated Expenses reached $69.1 million in Q4 2025 per NBIX's latest filing, up from $53.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $69.1 million in Q4 2025 to a low of $17.6 million in Q1 2022.
  • Average Other Accumulated Expenses over 5 years is $31.9 million, with a median of $21.6 million recorded in 2021.
  • Peak YoY movement for Other Accumulated Expenses: fell 9.5% in 2022, then skyrocketed 99.46% in 2024.
  • A 5-year view of Other Accumulated Expenses shows it stood at $20.0 million in 2021, then increased by 3.5% to $20.7 million in 2022, then skyrocketed by 73.43% to $35.9 million in 2023, then grew by 28.41% to $46.1 million in 2024, then soared by 49.89% to $69.1 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Other Accumulated Expenses are $69.1 million (Q4 2025), $53.7 million (Q3 2025), and $56.8 million (Q2 2025).